NCT06553547

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

CompletedPHASE2INTERVENTIONAL

Trial Details

Start: 2024-07-24Est. Completion: 2026-07-07

Enrollment target: 72 participants

Locations

Applied Research Center of Arkansas, Little Rock, Arkansas, United States
Connecticut Children's Medical Center, Hartford, Connecticut, United States
Waterway Research & Associates Corp., Miami, Florida, United States
Valencia Medical and Research Center, Miami, Florida, United States
Orlando Health, Inc.- APH Center for Digestive Health and Nutrition, Orlando, Florida, United States
Florida Pharmaceutical Research and Associates, Inc., South Miami, Florida, United States
OSF Saint Francis Medical Center, Peoria, Illinois, United States
Mankato Clinic Children's Health Center, Mankato, Minnesota, United States
Boys Town National Research Hospital, Boys Town, Nebraska, United States
SUNY Downstate Medical Center, Brooklyn, New York, United States
Wilmington Health, Wilmington, North Carolina, United States
Akron Children's Hospital, Akron, Ohio, United States
Prisma Health Children's Hospital, Greenville, South Carolina, United States
Maspons Pediatric Gastro, El Paso, Texas, United States
Proactive El Paso, LLC, El Paso, Texas, United States

Irritable Bowel SyndromeConstipation

The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and …

Mesa, United StatesEst. completion Jul 2027

Cystic FibrosisConstipation

Tenapanor is the newest FDA-approved drug for IBS with constipation (IBS-C). This study seeks to understand tenapanor as…

Boston, United StatesEst. completion Jun 15, 2026

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.